P. aeruginosais a ubiquitous gram-negative, aerobic rod-shaped, non-sporeformingbacterium. It is an opportunistic pathogen with highmortality due to a combination of weakened host defenses, antibiotic resistance, production of extracellular bacterial enzymes, toxinsand biofilm production. Bacteria within the biofilm can communicate with eachother, evade immune defenses, resistant microbial therapy, and obtain nutrients. The regulation of various processes important for the adaptation and survival of bacteria in the environment, such as biofilm production, is controlled by QS. P. aeruginosa infection can affect any part of the body. It is a common cause of nosocomial infections that manifest as pneumonia, surgical wound infections, urinary tract infections, or bacteremia. One ofthe most important aspects of controlling P. aeruginosa infections is prevention. Infections caused by this bacterium are difficult to cure due to its intrinsic and acquired antimicrobial resistance. Empiric treatment of P. aeruginosa infections often includes early combination therapy with two antipseudomonal antibiotics. Resistance of clinical isolates of P. aeruginosa to carbapenems is increasing. Acquisition of carbapenemase encoding genes is an extremely important mechanism. These βlactamases can hydrolyze carbapenems and confer resistance to almost all β-lactam antibiotics. Carbapenemases are not intrinsically expressed in P. aeruginosa, but are encoded by heterologous genes acquired by horizontal transfer and have epidemic potential.